Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as Zolgensma, could be approved for a broad range of spinal muscular atrophy ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

The recall has been issued for some products due to higher than acceptable levels of benzene, a chemical linked to leukemia and other blood disorders.

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche ... it is difficult to get this class of drug distributed through the brain and spinal ...